期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 91, 期 2, 页码 157-163出版社
WILEY
DOI: 10.1111/ejh.12135
关键词
Pneumocystis jirovecii pneumonia; prophylaxis; cancer; fludarabine; cyclophosphamide and rituximab; lymphocyte; guideline
类别
资金
- Gilead Sciences Inc.
- Merck
- Pfizer Australia
- Pfizer International
- Roche
Objective: Fludarabine, cyclophosphamide and rituximab (FCR) therapy for lymphoid malignancies has historically been associated with a low reported incidence of Pneumocystis jirovecii pneumonia (PJP). However, prophylaxis was routinely used in early studies, and molecular diagnostic tools were not employed. The objective of this study was to review the incidence of PJP during and post-FCR in the era of highly sensitive molecular diagnostics and F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)-computerised tomography (CT). Methods: All patients treated with standard FCR at the Peter MacCallum Cancer Centre (March 2009 to June 2012) were identified from a medications management database. Laboratory-confirmed PJP cases during this time were identified from an electronic database. Results: Overall, 66 patients were treated with a median of 5.5 FCR cycles. Eight PJP cases were identified, 6 of whom had received chemotherapy prior to FCR. In 5 cases, F-18-FDG PET demonstrated bilateral ground-glass infiltrates. Median CD4(+) lymphocyte counts at time of PJP diagnosis and 9-12months following FCR were 123 and 400cells/L, respectively. In patients receiving no prophylaxis, 9.1% developed PJP during FCR. The rate following FCR was 18.4%, with median onset at 6months (2.4-24months). Conclusion: Given the high rate of late-onset PJP, consideration should be given for extended PJP prophylaxis for up to 12months post-FCR, particularly in pretreated patients. Further evaluation of the role of CD4(+) monitoring is warranted to quantify risk of disease development and to guide duration of prophylaxis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据